Drug Trial Radar · NCT03834883
Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Mar 26, 2019
Primary completion
May 21, 2024
Study completion May 23, 2024
Sponsor
- Lead sponsor
- Indiana UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- American Heart Association; Purdue University
- First posted
- Feb 8, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 21 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This research will determine if oral progesterone attenuates drug-induced QT interval lengthening in a) Postmenopausal women 50 years of age or older, and b) Premenopausal women studied during the ovulation phase of the menstrual cycle. This investigation will consist of two concurrent prospective, randomized, double-blind, placebo-controlled crossover-design studies in a) Postmenopausal women, and b) Premenopausal women. Each subject will take progesterone or placebo capsules for 1 week. After a two-week "washout" (no progesterone or placebo) each subject will then take the alternative therapy (progesterone or placebo) for 1 week. After 7 days of each treatment, subjects will present to the clinical research center to receive a small dose of the QT interval-lengthening drug ibutilide, and the effect on the QT, J-Tpeak and Tpeak-Tend intervals during the progesterone and placebo phases will be compared
Conditions
- Long QT Syndrome
- Abnormalities, Drug-Induced
Interventions
ProgesteroneDrug
Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
IbutilideDrug
Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
Primary outcomes
What the sponsor says the trial is designed to measure.
- Baseline (Pre-ibutilide) QT-F IntervalsTime frame: After 7 days of treatment with oral progesterone or placebo, prior to receiving ibutilide
- Maximum Post-ibutilide QT-F IntervalsTime frame: Prior to ibutilide; at 5 minutes into the 10-minute ibutilide infusion; end of infusion; and at 5, 10, 15, 20, 30, and 45 minutes and 1, 2, 4, 6, and 8 hours after the ibutilide infusion
- % Change From Baseline (Pre-ibutilide) in Maximum QT-F IntervalsTime frame: Prior to ibutilide; at 5 minutes into the 10-minute ibutilide infusion; end of infusion; and at 5, 10, 15, 20, 30, and 45 minutes and 1, 2, 4, 6, and 8 hours after the ibutilide infusion
- Area Under the QT-F Versus Time Curves During and for 1 Hour Following Ibutilide InfusionTime frame: Prior to ibutilide; at 5 minutes into the 10-minute ibutilide infusion; end of infusion; and at 5, 10, 15, 20, 30, and 45 minutes and 1 hour after the ibutilide infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Indiana University
Indianapolis, Indiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.